Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
wishes to remind interested parties that it will hold a conference call
today, Thursday, June 19, 2014 at 4:00 p.m. EDT.
Management will discuss the outline of the Company’s planned phase 3
study of PV-10 in the treatment of melanoma and developments in the use
of PV-10 in other cancer indications including PV-10 in combination as
appropriate. It will also review PV-10 data presented in Chicago at ASCO
earlier in the month on June 2nd, as well as provide updates
on PH-10 and news regarding its use. Management will also discuss its
potential plans to monetize its PV-10 and PH-10 assets with various
contemplated license and co-development transactions.
The Company has submitted PV-10 phase 2 melanoma study results to www.clinicaltrials.gov
and will announce when these are published and become publicly
available. In the interim, the Company is providing data presented at
ASCO via this link: http://www.pvct.com/publications/ASCO-Poster-2014.pdf,
which contains the phase 3 study outline that the Company will discuss
on today’s conference call. Moffitt Cancer Center data presented at ASCO
is expected to be published in a future peer-reviewed journal
publication.
Those who wish to participate in the conference call may telephone
877-407-4019 from the U.S. International callers may telephone
201-689-8337 approximately 15 minutes before the call. A webcast will
also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours
after the completion of the call until August 19, 2014, and may be
accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for
International callers, and using the Conference ID#13584727.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. PV-10, its novel investigational drug for cancer,
is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This press release contains
"forward-looking statements" as defined under U.S. federal securities
laws. These statements reflect management's current knowledge,
assumptions, beliefs, estimates, and expectations and express
management's current views of future performance, results, and trends
and may be identified by their use of terms such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "will," and other similar terms. Forward-looking
statements are subject to a number of risks and uncertainties that could
cause our actual results to materially differ from those described in
the forward-looking statements. Readers should not place undue reliance
on forward-looking statements. Such statements are made as of the date
hereof, and we undertake no obligation to update such statements after
this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2014), and the
following:
-
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with a phase 3 trial of PV-10 to treat
locally advanced cutaneous melanoma and the costs associated with such
a trial if it is necessary;
-
our determination whether to license PV-10, our melanoma drug product
candidate, and other solid tumors such as liver cancer, if such
licensure is appropriate considering the timing and structure of such
a license, or to commercialize PV-10 on our own to treat melanoma and
other solid tumors such as liver cancer;
-
our ability to license our dermatology drug product candidate, PH-10,
on the basis of our phase 2 atopic dermatitis and psoriasis results,
which are in the process of being further developed in conjunction
with mechanism of action studies; and
-
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization.
Copyright Business Wire 2014